Post-Chemoradiation Metastatic, Persistent and Resistant Nodes in Locally Advanced Rectal Cancer: Metrics and Their Impact on Long-Term Outcome

por Calvo, Felipe A., Tudela, María, Serrano, Javier, Muñoz-Fernández, Mercedes, Peligros, María Isabel, Garcia-Alfonso, Pilar, del Valle, Emilio
Publicado 2023

Neoadjuvant therapy impact in early pancreatic cancer: “bioborderline” vs. “non-bioborderline”

por Taboada, Alvaro Gregorio Morales, Lominchar, Pablo Lozano, Martínez, María Fernández, García-Alfonso, Pilar, Martin, Andrés Muñoz, Asencio, Jose Manuel
Publicado 2022

Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clini...

por Chau, Ian, Fakih, Marwan, García-Alfonso, Pilar, Linke, Zdenĕk, Ruiz Casado, Ana, Marques, Eduardo Polo, Picard, Pascaline, Celanovic, Marina, Cartwright, Thomas
Publicado 2020

SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)

por Fernández Montes, Ana, Alonso, Vicente, Aranda, Enrique, Élez, Elena, García Alfonso, Pilar, Grávalos, Cristina, Maurel, Joan, Vera, Ruth, Vidal, Rosario, Aparicio, Jorge
Publicado 2023

Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status

por Blagoev, Krastan B., Wilkerson, Julia, Burotto, Mauricio, Kim, Chul, Espinal-Domínguez, Edward, García-Alfonso, Pilar, Alimchandani, Meghna, Miettinen, Markku, Blanco-Codesido, Montserrat, Fojo, Tito
Publicado 2017

Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades

por Taboada, Alvaro Gregorio Morales, Lominchar, Pablo Lozano, Roman, Lorena Martin, García-Alfonso, Pilar, Martin, Andres Jesús Muñoz, Rodriguez, Jose Antonio Blanco, Pascual, Jose Manuel Asencio
Publicado 2021

Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer

por García-González, Xandra, Cortejoso, Lucía, García, María I., García-Alfonso, Pilar, Robles, Luis, Grávalos, Cristina, González-Haba, Eva, Marta, Pellicer, Sanjurjo, María, López-Fernández, Luis A.
Publicado 2015

Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents

por García-Alfonso, Pilar, Ferrer, Ana, Gil, Silvia, Dueñas, Rosario, Pérez, María Teresa, Molina, Raquel, Capdevila, Jaume, Safont, María José, Castañón, Carmen, Cano, Juana María, Lara, Ricardo
Publicado 2015

Oral drugs in the treatment of metastatic colorectal cancer

por García-Alfonso, Pilar, Muñoz Martín, Andrés Jesús, Ortega Morán, Laura, Soto Alsar, Javier, Torres Pérez-Solero, Gabriela, Blanco Codesido, Montserrat, Calvo Ferrandiz, Pilar Aitana, Grasso Cicala, Silvina
Publicado 2021

Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer

por Vera, Ruth, Ibarrola-de-Andrés, Carolina, Adeva, Jorge, Pérez-Rojas, Judith, García-Alfonso, Pilar, Rodríguez-Gil, Yolanda, Macarulla, Teresa, Serrano-Piñol, Teresa, Mondéjar, Rebeca, Madrigal-Rubiales, Beatriz
Publicado 2022

Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review

por Trojan, Jörg, Mineur, Laurent, Tomášek, Jiří, Rouleau, Etienne, Fabian, Pavel, de Maglio, Giovanna, García-Alfonso, Pilar, Aprile, Giuseppe, Taylor, Aliki, Kafatos, George, Downey, Gerald, Terwey, Jan-Henrik, van Krieken, J. Han
Publicado 2015

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review

por Han van Krieken, J., Kafatos, George, Bennett, James, Mineur, Laurent, Tomášek, Jiří, Rouleau, Etienne, Fabian, Pavel, De Maglio, Giovanna, García-Alfonso, Pilar, Aprile, Giuseppe, Parkar, Parijan, Downey, Gerald, Demonty, Gaston, Trojan, Jörg
Publicado 2017

Single‐Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)

por García‐Alfonso, Pilar, Benavides, Manuel, Falcó, Esther, Muñoz, Andrés, Gómez, Auxiliadora, Sastre, Javier, Rivera, Fernando, Montagut, Clara, Salgado, Mercedes, López‐Ladrón, Amelia, López, Rafael, Ruiz de Mena, Inmaculada, Durán, Gema, Aranda, Enrique
Publicado 2018

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study

por Garcia-Alfonso, Pilar, Chaves, Manuel, Muñoz, Andrés, Salud, Antonieta, García-Gonzalez, Maria, Grávalos, Cristina, Massuti, Bartomeu, González-Flores, Encarna, Queralt, Bernardo, López-Ladrón, Amelia, Losa, Ferran, Gómez, Maria Jose, Oltra, Amparo, Aranda, Enrique
Publicado 2015

Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer

por Fogelman, David, Cubillo, Antonio, García‐Alfonso, Pilar, Mirón, María Luisa Limón, Nemunaitis, John, Flora, Daniel, Borg, Christophe, Mineur, Laurent, Vieitez, Jose M., Cohn, Allen, Saylors, Gene, Assad, Albert, Switzky, Julie, Zhou, Li, Bendell, Johanna
Publicado 2018

Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyse...

por Grothey, Axel, Yoshino, Takayuki, Bodoky, Gyorgy, Ciuleanu, Tudor, Garcia-Carbonero, Rocio, García-Alfonso, Pilar, Van Cutsem, Eric, Muro, Kei, Mytelka, Daniel S, Li, Li, Lipkovich, Olga, Hsu, Yanzhi, Sashegyi, Andreas, Ferry, David, Nasroulah, Federico, Tabernero, Josep
Publicado 2018

A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

por Gorbunova, Vera, Beck, J. Thaddeus, Hofheinz, Ralf-Dieter, Garcia-Alfonso, Pilar, Nechaeva, Marina, Cubillo Gracian, Antonio, Mangel, Laszlo, Elez Fernandez, Elena, Deming, Dustin A., Ramanathan, Ramesh K., Torres, Alison H., Sullivan, Danielle, Luo, Yan, Berlin, Jordan D.
Publicado 2018

Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

por Gorbunova, Vera, Beck, J. Thaddeus, Hofheinz, Ralf-Dieter, Garcia-Alfonso, Pilar, Nechaeva, Marina, Gracian, Antonio Cubillo, Mangel, Laszlo, Fernandez, Elena Elez, Deming, Dustin A., Ramanathan, Ramesh K., Torres, Alison H., Sullivan, Danielle, Luo, Yan, Berlin, Jordan D.
Publicado 2019

DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach

por Villalvazo, Priscila, Marzal-Alfaro, Belén, García-Alfonso, Pilar, Revuelta-Herrero, José Luis, Thomas, Fabienne, López-Tarruella, Sara, García-González, Xandra, Calvo, Aitana, Yakoubi, Malika, Salvador-Martín, Sara, López-López, Flora, Aguilar, Iker, Sanjurjo-Sáez, María, Martín, Miguel, López-Fernández, Luis Andrés
Publicado 2021

Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-secti...

por Capdevila, Jaume, Sevilla, Isabel, Alonso, Vicente, Antón Aparicio, Luís, Jiménez Fonseca, Paula, Grande, Enrique, Reina, Juan José, Manzano, José Luís, Alonso Lájara, Juan Domingo, Barriuso, Jorge, Castellano, Daniel, Medina, Javier, López, Carlos, Segura, Ángel, Carrera, Sergio, Crespo, Guillermo, Fuster, José, Munarriz, Javier, García Alfonso, Pilar
Publicado 2015